Therapy News and Research

RSS

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.

31 Jan 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.

31 Jan 2013

Bilateral and multiple ‘popping’ characterizes upper cervical HVLA

Cavitation during upper cervical high-velocity, low amplitude thrust manipulation is significantly more likely to occur bilaterally than unilaterally, say investigators.

31 Jan 2013

Interferon retreatment of chronic hepatitis C may be harmful

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library.

31 Jan 2013

Study finds serious long-term side effects following prostate cancer treatments

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment.

31 Jan 2013

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

In the framework of the World Cancer Day, the European Technology Platform of Nanomedicine (ETPN) and its partners will organize a European event on February the 1st on "How nanomedicine contributes to better cancer diagnostic and therapy". Similar and simultaneous events will be organized in France and Portugal, highlighting the importance of nanomedicine research for cancer on the European level.

31 Jan 2013

State roundup: Ga. hospital fee bill nears passage

After a series of friendly questions and statements of support, the fast-tracked legislation on a state hospital provider fee swept through a House committee Tuesday. The House Government Affairs Committee, by a 15-1 vote, approved Senate Bill 24, which would facilitate the renewal of the assessment. The state Senate passed the bill earlier this month. The legislation could reach the House floor Thursday or Friday. If it passes, it then would go to Gov. Nathan Deal for his signature -- an unusually rapid journey into law.

31 Jan 2013

Being married and cohabiting reduces risk of heart attack in both men and women in all age groups

A large population-based study from Finland has shown that being unmarried increases the risk of fatal and non-fatal heart attack in both men and women whatever their age. Conversely, say the study investigators, especially among middle-aged couples, being married and cohabiting are associated with "considerably better prognosis of acute cardiac events both before hospitalization and after reaching the hospital alive".

31 Jan 2013

No added benefit from linagliptin in patients with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market for Medicinal Products (AMNOG) again showed that no added benefit of the drug over the appropriate comparator therapy (ACT) can be determined, because the pharmaceutical company has not submitted any relevant studies.

31 Jan 2013

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Cell Therapeutics, Inc. (CTI) today announced that the Gynecologic Oncology Group (GOG) informed CTI that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

31 Jan 2013

Existing cardiomyocytes contribute to formation of new heart cells after attack

Injecting specialized cardiac stem cells into a patient's heart rebuilds healthy tissue after a heart attack, but where do the new cells come from and how are they transformed into functional muscle?

31 Jan 2013

NSU's College of Osteopathic Medicine receives approval for new medical specialty

Nova Southeastern University's College of Osteopathic Medicine (NSU-COM) received approval for a new medical specialty—correctional medicine—that was developed at the college in collaboration with the Florida Department of Corrections.

31 Jan 2013

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

31 Jan 2013

No proof of added benefit from aclidinium bromide in adults with COPD

The drug aclidinium bromide has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).

31 Jan 2013

No added benefit from perampanel in patients with epileptic fits

The drug perampanel has been approved since July 2012 as adjunctive therapy for adults and children aged 12 years and older with epileptic fits (seizures).

30 Jan 2013

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

QIAGEN N.V. today announced that Clarient - a GE Healthcare Company and leading provider of cancer laboratory testing services in the United States - has adopted the use of the therascreen KRAS RGQ PCR Kit (therascreen KRAS test) as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

From QIAGEN Manchester Limited 30 Jan 2013

UCSD molecular biologist to receive Charles Rodolphe Brupbacher Prize for Cancer Research

Molecular biologist Michael Karin is to receive this year's Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. The award, which carries CHF 100,000 in prize money, is considered one of the highest accolades for cancer researchers worldwide. The awards ceremony takes place in Zurich this Thursday in the framework of an international symposium on "Breakthroughs in Cancer Research and Therapy".

30 Jan 2013

Therapy News and Research

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Dual renin angiotensin system blockade: too many cons

Bilateral and multiple ‘popping’ characterizes upper cervical HVLA

Interferon retreatment of chronic hepatitis C may be harmful

Study finds serious long-term side effects following prostate cancer treatments

Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

State roundup: Ga. hospital fee bill nears passage

Being married and cohabiting reduces risk of heart attack in both men and women in all age groups

No added benefit from linagliptin in patients with type 2 diabetes

DSMB recommends continuation of CTI’s OPAXIO Phase 3 trial on ovarian cancer

Existing cardiomyocytes contribute to formation of new heart cells after attack

NSU's College of Osteopathic Medicine receives approval for new medical specialty

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

No proof of added benefit from aclidinium bromide in adults with COPD

No added benefit from perampanel in patients with epileptic fits

Clarient adopts QIAGEN’s therascreen KRAS test to diagnose colorectal cancer

UCSD molecular biologist to receive Charles Rodolphe Brupbacher Prize for Cancer Research

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News